NPI 1386736627: Open Payments
NPI 1386736627. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 29 payments from 7 companies in 2025. Trend: 2023 $1,704 · 2024 $1,048 · 2025 $687
Food & beverage: $681Education: $5
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $270 |
| Janssen Pharmaceuticals, Inc | 10 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $19 |
| ABBVIE INC. | 1 | $15 |
Products named: ABILIFY MAINTENA, INVEGA SUSTENNA, CAPLYTA, REXULTI, AUSTEDO XR, UZEDY, SPRAVATO, ABILIFY ASIMTUFII.
